Clinical Pipeline
Active Development
Our portfolio of neuro-therapeutic candidates spans from preclinical discovery through Phase III registration, all leveraging the VN-Platform™ delivery technology.
Development Stage Tracker
Neuro-Stabilin™
Treatment-Resistant Depression (TRD)
Cortexin-B™
Early-Stage Alzheimer’s Disease
Synaptrol™
Parkinson’s Disease Motor Symptoms
Myeloguard™
Multiple Sclerosis (Relapsing)
Nocturex™
Chronic Insomnia (Circadian)
Candidate Profiles
Neuro-Stabilin™
Treatment-Resistant Depression (TRD)
Novel neuro-active stabilizer targeting serotonergic and glutamatergic pathways with enhanced BBB penetration.
Cortexin-B™
Early-Stage Alzheimer’s Disease
Amyloid-targeting compound utilizing Xylothrin™ delivery platform for improved CNS bioavailability.
Synaptrol™
Parkinson’s Disease Motor Symptoms
Dopaminergic modulator with controlled-release profile designed for sustained motor symptom management.
Interested in partnership opportunities?
Access detailed program data, CoAs, and procurement information through our secure partner portal.